Safety of intravenous immunoglobulin treatment

Expert Opinion on Drug Safety

Volumn 9, Issue 6, 2010, Pages 971-979

  Caress, James B ^a   Kennedy, Burton L ^a   Eickman, Kara D ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse events; Intravenous immunoglobulin; Renal failure; Safety; Thromboembolism

Indexed keywords

ANTIHISTAMINIC AGENT; CARIMUNE; CORTICOSTEROID; DIPHENHYDRAMINE; GAMMAPLEX; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; PARACETAMOL; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ALOPECIA; ANAPHYLAXIS; ASEPTIC MENINGITIS; AUTOIMMUNE DISEASE; CARDIOVASCULAR RISK; CHILL; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CHRONIC LYMPHATIC LEUKEMIA; DEATH; DERMATOMYOSITIS; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA MULTIFORME; ERYTHROCYTE; FATIGUE; FLUSHING; FOCAL GLOMERULONEPHRITIS; FOOD AND DRUG ADMINISTRATION; GUILLAIN BARRE SYNDROME; HEADACHE; HEART INFARCTION; HEART PALPITATION; HOARSENESS; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNOGLOBULIN A NEPHROPATHY; LEUKOCYTE COUNT; LUNG EMBOLISM; MALAISE; MEMBRANOUS GLOMERULONEPHRITIS; MONOCYTE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIPLE SCLEROSIS; MYALGIA; MYASTHENIA GRAVIS; NAUSEA; NEUTROPENIA; NEUTROPHIL; PROTEINURIA; PRURITUS; RASH; REVIEW; SIDE EFFECT; STROKE; THROMBOCYTE; THROMBOCYTOPENIA; TREATMENT RESPONSE; URTICARIA; VEIN THROMBOSIS;

AUTOIMMUNE DISEASES; COMMON VARIABLE IMMUNODEFICIENCY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS;

EID: 77958029506     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2010.484419     Document Type: Review

References (58)

1. Imbach P, Barundun S, d'Apuzzo V, et al. High dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1(8232):1228-1231
2. Lemieux R, Bazin R, Néron S. Therapeutic intravenous immunoglobulins. Mol Immunol 2005;42:839-848
3. Dalakas MC. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating polyneuropathies. Neurology 2002;59(12 Suppl 6):S13-21
4. Caress JB, Hobson-Webb L, Passmore LV, et al. Case-control study of thromboembolic events associated with IV immunoglobulin. J Neurol 2009;256:339-342
5. Marie I, Maurey G, Herve F, et al. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol 2006;155:714-721
6. Gurcan HM, Ahmed AR. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus and pemphigoid. Ann Pharmacother 2007;41:1604-1610
7. Katz U, Achiron A, Sherer Y, et al. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmunity Rev 2007;6:257-259
8. Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2006;6:535-542
9. Wittstock M, Zettl UK. Adverse effects of treatment with intravenous immunoglobulins for neurological diseases. J Neurol 2006;253:V/75-V/79
10. Nettis E, Calogiuri G, Colanardi MC, et al. Drug-induced aseptic meningitis. Curr Drug Targets Immune Endocr Metab Disord 2003;3:143-149
11. Obando I, Duran I, Martin-Rosa L, et al. Aseptic meningitis due to administration of intravenous immunoglobulin with an unusually high number of leukocytes in cerebrospinal fluid. Pediatr Emerg Care 2002;18:429-432
12. Vacchietti G, Kerl K, Prins C, et al. Severe eczaematous skin reaction after high-dose intravenous immunoglobulin infusion. Arch Dermatol 2006;142:213-217
13. Woodruff RK, Grigg AP, Firkin FC, et al. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients [letter]. Lancet 1986;2:217-218
14. Caress JB, Cartwright MS, Donofrio PD, et al. The clinical features of 16 cases of stroke associated with administration of IVIG. Neurology 2003;60(11):1822-1824
15. U.S. Food and Drug Administration. 16 October 2003. Available from: http:// www.fda.gov/cber/ltr/igiv101603.htm. [Accessed 13 October 2005]
16. Wada Y, Kamei A, Fujii Y, et al. Cerebral infarction after high-dose intravenous immunoglobulin therapy for Kawasaki disease. J Pediatr 2006;148:399-400
17. Paran D, Herishanu Y, Eljayam O, et al. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis 2005;16:313-318
18. Okuda D, Flaster M, Frey J, et al. Arterial thrombosis induced by IVIg and its treatment with tPA. Neurology 2003;60:1825-1826
19. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism in hospitalized neutropenic patients. J Clin Oncol 2006;24:484-490
20. Voltz R, Rosen FV, Yousry T, et al. Reversible encephalopathy with cerebral vasospasm in a Gullain-Barré syndrome patient treated with intravenous immunoglobulin. Neurology 1996;46:250-251
21. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994;44:223-226
22. Crawford J, Cox EB, Cohen HJ. Evaluation of hyperviscosity in monoclonal gammopathies. Am J Med 1985;79:13-22
23. Schiavotto C, Ruggeri M, Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica 1993;78(6 Suppl 2):35-40
24. Manke H, Seifert J. Anaphylactic shock reaction following intravenous administration of 7S immunoglobulin in patients with hypogammaglobulinemia, especially in children with acute lymphoblastic leukemia (ALL). Klin Pediatr 1987;199(4):274-278
25. Knezevic-Maramica I, Kruskall MS. Intravenous immune globulins: an update for clinicians. Transfusion 2003;43:1460-1480
26. Bollee G, Anglicheau D, Loupy A, et al. High-dosage intravenous immunoglobulin-associated macrovacuoles are associated with chronic tubulointerstitial lesion worsening in renal transplant recipients. Clin J Am Soc Nephrol 2008;3:1461-1468
27. Bolignano D, Coppolino G, Aloisi C, et al. Effect of a single intravenous immunoglobulin infusion on neutrophil gelatinase-associated lipoclain levels inn proteinuric patients with normal renal function. J Invest Med 2008;56:997-1003
28. Dephnis E, Stylianou K, Alexandrakis M, et al. Acute renal failure, translocational hyponatremia and hyperkalemia following intravenous immunoglobulin therapy. Nephron Clin Pract 2007;106:c143-48
29. Sevinc A, Camci C, Buyukberber S, et al. Intravenous gammaglobulininduced chronic renal failure in a patient with multiple myeloma. Med Oncol 2007;24:357-359
30. Vo A, Cam V, Toyoda M, et al. Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience. Clin J Am Soc Nephrol 2006;1:844-852
31. Katz U, Kishner I, Magalashvili D. Long term safety of IVIg therapy in multiple sclerosis: 10 years experience. Autoimmunity 2006;39:513-517
32. Tufan F, Kamali S, Erer B, et al. Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases. Clin Rhematol 2007;26:1913-1915
33. Chacko B, John GT, Balakrishnan JN, et al. Osmotic nephropathy resulting from maltose-based intravenous immunoglobulin therapy. Ren Fail 2006;28:193-195
34. Dickenmann M, Oetti T, Mihatsch MJ. Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. Am J Kidney Dis 2008;51:491-503
35. Siegel J. Safety considerations in IGIV utilization. Int Immunopharmacol 2006;6:523-527
36. Hellstern P, Sachse H, Schwinn H, et al. Manufacture and in-vitro characterization of a solvent/detergent-treated human plasma. Vox Sang 1992;63:178-185
37. Ballow M. Intravenous immunoglobulins: clinical experience and viral safety. J Am Pharm Assoc 2002;42:449-458
38. Hayakawa F, Imada K, Towatari M, Saito H. Life-threatening human parvovirus B19 infection transmitted by intravenous immune globulin. Br J Haematol 2002;118(4):1187-1189
39. Erdman DD, Anderson BC, Torok TJ, et al. Possible transmission of parvovirus B19 from intravenous immune globulin. J Med Virol 1997;53(3):233-236
40. Llewelyn CA, Hewitt PA, Knight RSG, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004;363:417-421
41. Health Protection Agency: New case of transfusion-associated variant-CJD. Commun Dis Rep CDR Wkly [serial online] 2006;16(6):News
42. Peden AH, Head MW, Ritchie DL, et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004;364:527-529
43. Stucki M, Boschetti N, Schäfer W, et al. Investigations of prion and virus safety of a new liquid IVIG product. Biologicals 2008;36:239-247
44. Kaminski HJ. Myasthenia gravis. Neuromuscular disorders. Butterworth Heinemann 2002;50:916-930
45. Daya S, Gunby J, Clark DA. Intravenous immunoglobulin therapy for recurrent spontaneous abortion: a meta-analysis. Am J Reprod Immunol 1998;39(2):69-76
46. Berger M. Principles of and advancements in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin N Am 2008;28:413-437
47. Lemos S, Jacob CMA, Pastorino AC, et al. Neutropenia in antibody-deficient patients under IVIG replacement therapy. Pediatr Allergy Immunol 2009;20:97-101
48. Niebanck AE, Kwiatkowski JL, Raffini LJ. Neutropenia following IVIG therapy in pediatric patients with immune-mediated thrombocytopenia. J Pediatr Hematol Oncol 2005;27:145-147
49. Matsuda M, Hosoda W, Sekijima Y, et al. Neutropenia as a complication of high-dose intravenous immunoglobulin therapy in adult patients with neuroimmunologic disorders. Clin Neuropharm 2003;26:306-311
50. Nguyen MK, Rastogi A, Kurtz I. True hyponatremia secondary to intravenous immunoglobulin. Clin Esp Nephrol 2006;10:124-126
51. Steinberger BA, Ford SM, Coleman TA. Intravenous immunoglobulin therapy results in post-infusional hyperproteinemia, increased serum viscosity, and pseudohyponatremia. Am J Hematol 2003;73:97-100
52. Bern M. Clinically significant pseudohyponatremia. Am J Hematol 2006;81:558-559
53. Gaines AR, Pierce LR, Bernhardt PA. Fatal iatrogenic hypoglycemia: falsely elevated blood glucose readings with a point-of-care meter due to a maltose-containing intravenous immune globulin product. FDA MedWatch Safety Alert-FDA reminds healthcare professionals about falsely elevated glucose levels. 9 November 2005. Available from: www.fda.gov/ BiologicsBloodVaccines/ SafetyAvailability/ucm155099.htm [Last accessed 1 November 2009]
54. Ochs HD, Gupta S, Kiessling P, et al. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006;26:265-273
55. Gardulf A, Nicolay U, Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies-a prospective, multi-national study. J Clin Immunol 2006;26:177-185
56. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol 2004;112:1-7
57. Lee D, Linker RA, Paulus W, et al. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2008;37:406-409
58. Grillo JA, Gorson KC, Ropper AH, et al. Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders. Neurology 2001;57:1699-1701